Oncolytics Biotech Q2 2025 Earnings Report

Oncolytics Biotech EPS Results

• Actual EPS: -$0.05
• Consensus EPS: -$0.11
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Oncolytics Biotech Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oncolytics Biotech Announcement Details

• Quarter: Q2 2025
• Date: 8/8/2025
• Time: Before Market Opens
• Conference Call Date: Friday, August 8, 2025
• Conference Call Time: 10:00AM ET

Oncolytics Biotech (NASDAQ:ONCY) (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers. Collaborations with academic centers and pharmaceutical partners support ongoing research into optimal dosing regimens, novel combination strategies and biomarker identification. The company also maintains an early-stage pipeline of additional viral candidates aimed at broadening its platform of immune‐activating cancer therapies.

Headquartered in Calgary, Alberta, with a research and development facility in Houston, Texas, Oncolytics sustains a presence in major North American life science hubs. The company’s infrastructure supports integrated translational research, process development and global clinical trial management, with a focus on advancing regulatory filings and securing strategic partnerships to accelerate commercialization.

Under the leadership of President and Chief Executive Officer Brad Thompson, Oncolytics’ management team brings extensive experience in oncology drug development, virology and biopharmaceutical operations. The company remains committed to advancing its viral immunotherapy platform through rigorous clinical investigation and collaborative programs designed to address unmet needs in oncology.